Document is current
Any future updates will be listed below
-
Authors
Yonesaka, Kimio https://orcid.org/0000-0002-0816-5315
Iwama, Eiji
Hayashi, Hidetoshi
Suzuki, Shinichiro
Kato, Ryoji
Watanabe, Satomi
Takahama, Takayuki
Tanizaki, Junko
Tanaka, Kaoru
Takeda, Masayuki
Sakai, Kazuko
Azuma, Koichi
Chiba, Yasutaka
Atagi, Shinji
Nishio, Kazuto
Okamoto, Isamu
Nakagawa, Kazuhiko https://orcid.org/0000-0003-1284-9776
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
AstraZeneca
F. Hoffmann-La Roche Ltd | Chugai Pharmaceutical
Taiho Pharmaceutical
Bristol-Myers Squibb
Eli Lilly and Company
Merck & Co., Inc. | MSD K.K.
Merck & Co., Inc. | MSD K.K.
Merck & Co., Inc. | MSD K.K.
Pfizer Inc. | Pfizer Japan
Merck & Co., Inc. | MSD K.K.
Astellas Pharma
Novartis Pharmaceuticals Corporation
AbbVie
Takeda Pharmaceutical Company
Daiichi Sankyo Company
Merck & Co., Inc. | MSD K.K.
- License Information
-
More Information
Article History
Received: 19 May 2019
Accepted: 5 December 2019
First Online: 20 December 2019
Competing interests
: Dr. Iwama reports personal fees from AstraZeneca. Atagi reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from MSD, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Taiho, grants and personal fees from Ono, grants and personal fees from Pfizer, grants and personal fees from Bristol-Myers Squibb, personal fees from Hisamitsu. Azuma reports personal fees from Boehringer Ingelheim, personal fees from AstraZeneca. Hayashi reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, grants from Chugai. Nishio reports grants from Boehringer Ingelheim. Takahama reports personal fees from Boehringer Ingelheim, personal fees from AstraZeneca. Takeda reports personal fees from Boehringer Ingelheim. Tanaka reports personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, personal fees from MSD Oncology. Tanizaki reports personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Eli Lilly, personal fees from MSD Oncology. Dr. Okamoto reports grants and personal fees from AstraZeneca, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD Oncology, grants and personal fees from Lilly, grants from Astellas Pharma, grants and personal fees from Bristol-Myers Squibb, grants from Novartis, grants and personal fees from Chugai Pharma, personal fees from Pfizer, grants from AbbVie. Yonesaka reports grants and personal fees from Boehringer Ingelheim. Nakagawa reports grants and personal fees from AstraZeneca, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD Oncology, grants and personal fees from Lilly, grants and personal fees from Astellas Pharma, grants and personal fees from Bristol-Myers Squibb, grants from Novartis, grants and personal fees from Chugai Pharma, personal fees from Pfizer, grants from AbbVie, grants and personal fees from Takeda Pharma, grants and personal fees from Daiichi-sankyo.
